Clinical implication of genetic intratumor heterogeneity for targeted therapy in head and neck cancer

References

• Zhang XC, Xu C, Mitchell RM, et al. Tumor evolution and intratumor heterogeneity of an oropharyngeal squamous cell carcinoma revealed by whole-genome sequencing. Neoplasia. 2013;15(12):1371–1378. doi:10.1593/neo.131400.
   PubMed Web of Science ®Google Scholar
• Canning M, Guo G, Yu M, et al. Heterogeneity of the head and neck squamous cell carcinoma immune landscape and its impact on immunotherapy. Front Cell Dev Biol. 2019;7(APR):52. doi:10.3389/fcell.2019.00052.
   PubMed Web of Science ®Google Scholar
• Mroz EA, Tward AM, Hammon RJ, et al. Intra-tumor genetic heterogeneity and mortality in head and neck cancer: analysis of data from the cancer genome atlas. PLoS Med. 2015;12(2):e1001786. doi:10.1371/journal.pmed.1001786.
   PubMed Web of Science ®Google Scholar
• Abécassis J, Hamy AS, Laurent C, et al. Assessing reliability of intra-tumor heterogeneity estimates from single sample whole exome sequencing data. PLoS One. 2019;14(11):e0224143. doi:10.1371/journal.pone.0224143.
   PubMed Web of Science ®Google Scholar
• Rasmussen JH, Lelkaitis G, Håkansson K, et al. Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. Br J Cancer. 2019;120(10):1003–1006. doi:10.1038/s41416-019-0449-y.
   PubMed Web of Science ®Google Scholar
• Bedard PL, Hansen AR, Ratain MJ, et al. Tumour heterogeneity in the clinic. Nature. 2013;501(7467):355–364. doi:10.1038/nature12627.
   PubMed Web of Science ®Google Scholar
• Yap TA, Gerlinger M, Futreal PA, et al. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med. 2012;4(127):127ps10. Mar. doi:10.1126/scitranslmed.3003854.
   PubMed Web of Science ®Google Scholar
• Pérez Sayáns M, Chamorro Petronacci CM, Lorenzo Pouso AI, et al. Comprehensive genomic review of TCGA Head and Neck Squamous Cell Carcinomas (HNSCC). J Clin Med. 2019;8(11):1896. doi:10.3390/jcm8111896.
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Sougnez C, Lichtenstein L, et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–582.
   PubMed Web of Science ®Google Scholar
• Mroz EA, Rocco JW. The challenges of tumor genetic diversity. Cancer. 2017;123(6):917–927. doi:10.1002/cncr.30430.
   PubMed Web of Science ®Google Scholar
• Kürten CHL, Kulkarni A, Cillo AR, et al. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nat Commun. 2021;12(1):7338. doi:10.1038/s41467-021-27619-4.
   PubMed Web of Science ®Google Scholar
• Schinke H, Shi E, Lin Z, et al. A transcriptomic map of EGFR-induced epithelial-to-mesenchymal transition identifies prognostic and therapeutic targets for head and neck cancer. Mol Cancer. 2022;21(1):178. doi:10.1186/s12943-022-01646-1.
   PubMed Web of Science ®Google Scholar
• Puram SV, Tirosh I, Parikh AS, et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell. 2017;171(7):1611–1624.e24. doi:10.1016/j.cell.2017.10.044.
   PubMed Web of Science ®Google Scholar
• Gaździcka J, Gołąbek K, Strzelczyk JK, et al. Epigenetic modifications in head and neck cancer. Biochem Genet. 2020;58(2):213–244. doi:10.1007/s10528-019-09941-1.
   PubMed Web of Science ®Google Scholar
• Christgen M, Bartels S, van Luttikhuizen JL, et al. Subclonal analysis in a lobular breast cancer with classical and solid growth pattern mimicking a solid-papillary carcinoma. J Pathol Clin Res. 2017;3(3):191–202. doi:10.1002/cjp2.76.
   PubMedGoogle Scholar
• Cao W, Wu W, Yan M, et al. Multiple region whole-exome sequencing reveals dramatically evolving intratumor genomic heterogeneity in esophageal squamous cell carcinoma. Oncogenesis. 2015;4(11):e175. doi:10.1038/oncsis.2015.34.
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–892. doi:10.1056/NEJMoa1113205.
   PubMed Web of Science ®Google Scholar
• Østrup O, Ahlborn LB, Lassen U, et al. Detection of copy number alterations in cell-free tumor DNA from plasma. BBA Clin. 2017;7:120–126. doi:10.1016/j.bbacli.2017.03.006.
   PubMed Web of Science ®Google Scholar
• Rasmussen JH, Olin AB, Lelkaitis G, et al. Intratumor heterogeneity is biomarker specific and challenges the association with heterogeneity in multimodal functional imaging in head and neck squamous cell carcinoma. Eur J Radiol. 2021;139:109668. doi:10.1016/j.ejrad.2021.109668.
   PubMed Web of Science ®Google Scholar
• Esteves L, Caramelo F, Ribeiro IP, et al. Probability distribution of copy number alterations along the genome: an algorithm to distinguish different tumour profiles. Sci Rep. 2020;10(1):14868. doi:10.1038/s41598-020-71859-1.
   PubMed Web of Science ®Google Scholar
• Leemans CR, Braakhuis BJM, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11(1):9–22. doi:10.1038/nrc2982.
   PubMed Web of Science ®Google Scholar
• Hoesli RC, Ludwig ML, Michmerhuizen NL, et al. Genomic sequencing and precision medicine in head and neck cancers. Eur J Surg Oncol. 2017;43(5):884–892. doi:10.1016/j.ejso.2016.12.002.
   PubMed Web of Science ®Google Scholar
• Cramer JD, Burtness B, Le QT, et al. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019;16(11):669–683. doi:10.1038/s41571-019-0227-z.
   PubMed Web of Science ®Google Scholar
• Marret G, Bièche I, Dupain C, et al. Genomic alterations in head and neck squamous cell carcinoma: level of evidence according to ESMO scale for clinical actionability of molecular targets (ESCAT). J Clin Oncol Precis Oncol. 2021;5:215–226. doi:10.1200/PO.20.00280.
   PubMed Web of Science ®Google Scholar
• Mateo J, Chakravarty D, Dienstmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018;29(9):1895–1902. doi:10.1093/annonc/mdy263.
   PubMed Web of Science ®Google Scholar
• Rasmussen JH, Olin A, Lelkaitis G, et al. Does multiparametric imaging with 18F-FDG-PET/MRI capture spatial variation in immunohistochemical cancer biomarkers in head and neck squamous cell carcinoma? Br J Cancer. 2020;123(1):46–53. doi:10.1038/s41416-020-0876-9.
   PubMed Web of Science ®Google Scholar
• QIAGEN. GeneRead DNA FFPE Handbook. GeneRead DNA FFPE Handb. 2014;(February):1–18. https://www.qiagen.com/us/resources/download.aspx?id=e8894854-8dc7-4318-8b1f-fa094286e4c0&lang=en
   Google Scholar
• Ciriello G, Miller ML, Aksoy BA, et al. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013;45(10):1127–1133. doi:10.1038/ng.2762.
   PubMed Web of Science ®Google Scholar
• Sulc Z, Cibulkova J, Rezankova H, et al. nomclust: hierarchical cluster analysis of nominal data. R package version 2.5.0. 2021. https://cran.r-project.org/package=nomclust
   Google Scholar
• Gleber-Netto FO, Rao X, Guo T, et al. Variations in HPV function are associated with survival in squamous cell carcinoma. JCI Insight. 2019;4(1):1–17. doi:10.1172/jci.insight.124762.
   Web of Science ®Google Scholar
• Sidiropoulos N, Sohi SH, Pedersen TL, et al. SinaPlot: an enhanced chart for simple and truthful representation of single observations over multiple classes. J Comput Graph Stat. 2018;27(3):673–676. doi:10.1080/10618600.2017.1366914.
   Web of Science ®Google Scholar
• Hernandez AL, Young CD, Wang JH, et al. Lessons learned from SMAD4 loss in squamous cell carcinomas. Mol Carcinog. 2019;58(9):1648–1655. doi:10.1002/mc.23049.
   PubMed Web of Science ®Google Scholar
• Klinakis A, Rampias T. TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection. EBioMedicine. 2020;58:102905. doi:10.1016/j.ebiom.2020.102905.
   PubMed Web of Science ®Google Scholar
• Squarize CH, Castilho RM, Abrahao AC, et al. PTEN deficiency contributes to the development and progression of head and neck cancer. Neoplasia. 2013;15(5):461–471. doi:10.1593/neo.121024.
   PubMed Web of Science ®Google Scholar
• Maiti GP, Mondal P, Mukherjee N, et al. Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes. PLoS One. 2013;8(5):e63440. doi:10.1371/journal.pone.0063440.
   PubMed Web of Science ®Google Scholar
• Field JK, Spandidos DA, Stell PM, et al. Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene an Int Journal. 1989;4(12):1463–1468.
   PubMed Web of Science ®Google Scholar
• Rodrigo JP, Lazo PS, Ramos S, et al. MYC amplification in squamous cell carcinomas of the head and neck. Arch Otolaryngol Head Neck Surg. 1996;122(5):504–507. doi:10.1001/archotol.1996.01890170038008.
   PubMedGoogle Scholar
• Suda T, Hama T, Kondo S, et al. Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma. BMC Cancer. 2012;12(1):416. doi:10.1186/1471-2407-12-416.
   PubMed Web of Science ®Google Scholar
• Shah PA, Huang C, Li Q, et al. NOTCH1 signaling in head and neck squamous cell carcinoma. Cells. 2020;9(12):2677. doi:10.3390/cells9122677.
   PubMed Web of Science ®Google Scholar
• Dolly SO, Gurden MD, Drosopoulos K, et al. RNAi screen reveals synthetic lethality between cyclin G-associated kinase and FBXW7 by inducing aberrant mitoses. Br J Cancer. 2017;117(7):954–964. doi:10.1038/bjc.2017.277.
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Licitra LF, Burtness B, et al. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. Ann Oncol. 2017;28(10):2526–2532. doi:10.1093/annonc/mdx344.
   PubMed Web of Science ®Google Scholar
• Nogova L, Sequist LV, Garcia JMP, et al. Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patientswith advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion stud. J Clin Oncol. 2017;35(2):157–165. doi:10.1200/JCO.2016.67.2048.
   PubMed Web of Science ®Google Scholar
• Burtness B, Rischin D, Greil R, et al. Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death ligand-1 combined positive score. J Clin Oncol. 2022;40(21):2321–2332. doi:10.1200/JCO.21.02198.
   Web of Science ®Google Scholar
• Zhao P, Su X, Ge T, et al. Pathway-specific genome editing of PI3K/mTOR tumor suppressor genes reveals that PTEN loss contributes to cetuximab resistance in head and neck cancer. Physiol Behav. 2016;176(1):139–148.
   Google Scholar
• Dumbrava EE, Johnson ML, Tolcher AW, et al. First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation. J Clin Oncol. 2022;40(16_suppl):3003–3003. doi:10.1200/JCO.2022.40.16_suppl.3003.
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Wu B, Williams K, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Am J Cancer Res. 2015;15(3):668–679. http://genomebiology.com/2014/15/8/448
   Google Scholar
• van Dijk E, van den Bosch T, Lenos KJ, et al. Chromosomal copy number heterogeneity predicts survival rates across cancers. Nat Commun. 2021;12(1):3188. doi:10.1038/s41467-021-23384-6.
   PubMed Web of Science ®Google Scholar
• van de Haar J, Hoes LR, Roepman P, et al. Limited evolution of the actionable metastatic cancer genome under therapeutic pressure. Nat Med. 2021;27(9):1553–1563. doi:10.1038/s41591-021-01448-w.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang X, Jia Y, et al. Intratumoural heterogeneity and clone evolution of oral squamous cell carcinoma. Mol Carcinog. 2021;60(11):758–768. doi:10.1002/mc.23341.
   PubMed Web of Science ®Google Scholar
• Zandberg DP, Tallon LJ, Nagaraj S, et al. Intratumor genetic heterogeneity in squamous cell carcinoma of the oral cavity. Head Neck. 2019;41(8):2514–2524. doi:10.1002/hed.25719.
   PubMed Web of Science ®Google Scholar
• Gabrielaite M, Torp MH, Rasmussen MS, et al. A comparison of tools for copy-number variation detection in germline whole exome and whole genome sequencing data. Cancers (Basel). 2021;13(24):6283. doi:10.3390/cancers13246283.
   PubMed Web of Science ®Google Scholar
• Silver AJ, Warner JL. ESCAT: a step in the right direction. Ann Oncol. 2018;29(11):2266–2267. doi:10.1093/annonc/mdy409.
   PubMed Web of Science ®Google Scholar
• Gyawali B, Kesselheim AS. The promise of ESCAT: a new system for evaluating cancer drug–target pairs. Nat Rev Clin Oncol. 2019;16(3):147–148. doi:10.1038/s41571-018-0110-3.
   PubMed Web of Science ®Google Scholar
• Luo W. Nasopharyngeal carcinoma ecology theory: cancer as multidimensional spatiotemporal “Unity of ecology and evolution” pathological ecosystem. Theranostics. 2023;13(5):1607–1631. doi:10.7150/thno.82690.
   PubMed Web of Science ®Google Scholar